DTC advertising planned for `NuvaRing', changes suggested by AstraZeneca

Author：

ISSN： 1173-5503

Source： PharmacoEconomics and Outcomes News, Vol.1, Iss.491, 2005-01, pp. : 14-14

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

In the year to March 2002, spending on direct-to-consumer (DTC) advertising for a single product in the US was highest for AstraZeneca's esomeprazole [`Nexium'] at $US177 million

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 398, 2003-01 ,pp. : 16-16

Adis International

Access to resources Recommend Favorite

An agreement reached with AstraZeneca will allow

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 387, 2002-01 ,pp. : 7-7

Adis International

Access to resources Recommend Favorite

AstraZENeca and the A&RT of metadata maintenance

By Frost Paul A A.

Pharmaceutical Programming, Vol. 3, Iss. 2, 2010-12 ,pp. : 57-63

Maney Publishing

Access to resources Recommend Favorite

Iressa linked to tumour haemorrhage, warns AstraZeneca

Reactions Weekly, Vol. 1, Iss. 1132, 2006-01 ,pp. : 1-1

Adis International

Access to resources Recommend Favorite

Molecular pathology in oncology – the AstraZeneca perspective

By Campbell David A Carmichael James Chopra Rajesh

Pharmacogenomics, Vol. 5, Iss. 8, 2004-12 ,pp. : 1167-1173

Future Medicine

Access to resources Recommend Favorite